Literature DB >> 32999210

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human.

Isao Muraki1.   

Abstract

Entities:  

Year:  2020        PMID： 32999210      PMCID： PMC8147015          DOI： 10.5551/jat.ED144

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  10 in total

Review 1.  Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment.

Authors:  Samuel M Cohen; Lora L Arnold; Michal Eldan; Ari S Lewis; Barbara D Beck
Journal:  Crit Rev Toxicol       Date:  2006-02       Impact factor: 5.635

2.  Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study.

Authors:  Kunihiro Nishimura; Tomonori Okamura; Makoto Watanabe; Michikazu Nakai; Misa Takegami; Aya Higashiyama; Yoshihiro Kokubo; Akira Okayama; Yoshihiro Miyamoto
Journal:  J Atheroscler Thromb       Date:  2014-03-25       Impact factor: 4.928

3.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

4.  Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.

Authors:  Karin Leander; Anders Mälarstig; Ferdinand M Van't Hooft; Craig Hyde; Mai-Lis Hellénius; Jason S Troutt; Robert J Konrad; John Öhrvik; Anders Hamsten; Ulf de Faire
Journal:  Circulation       Date:  2016-02-19       Impact factor: 29.690

5.  Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.

Authors:  Salim S Virani; Alvaro Alonso; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Amanda Marma Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Lisa B VanWagner; Connie W Tsao
Journal:  Circulation       Date:  2020-01-29       Impact factor: 29.690

6.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

7.  Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.

Authors:  Martine Paquette; Dany Gauthier; Ann Chamberland; Annik Prat; Emanuella De Lucia Rolfe; Jon J Rasmussen; Lydia Kaduka; Nabil G Seidah; Sophie Bernard; Dirk L Christensen; Alexis Baass
Journal:  Clin Biochem       Date:  2020-01-20       Impact factor: 3.281

Review 8.  Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis.

Authors:  Wan-Chin Kuo; Jennifer M Stevens; Anne L Ersig; Heather M Johnson; Tsan-Hua Tung; Lisa C Bratzke
Journal:  Curr Atheroscler Rep       Date:  2020-06-16       Impact factor: 5.113

9.  Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.

Authors:  Hitoshi Hamamura; Hisashi Adachi; Mika Enomoto; Ako Fukami; Sachiko Nakamura; Yume Nohara; Nagisa Morikawa; Akiko Sakaue; Kenta Toyomasu; Maki Yamamoto; Yoshihiro Fukumoto
Journal:  J Atheroscler Thromb       Date:  2020-07-04       Impact factor: 4.928

10.  Replacing Saturated Fats with Unsaturated Fats from Walnuts or Vegetable Oils Lowers Atherogenic Lipoprotein Classes Without Increasing Lipoprotein(a).

Authors:  Alyssa M Tindall; Penny M Kris-Etherton; Kristina S Petersen
Journal:  J Nutr       Date:  2020-01-07       Impact factor: 4.798
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.